Published works



  • 217 Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury. Nephrology (Carlton). 2023
    doi: 10.1111/nep.14254. PubMed
  • 206 Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. J Am Heart Assoc.2023
    doi: 10.1161/JAHA.122.028146. PubMed
  • 205 Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients. Int Urol Nephrol.2023
    doi: 10.1007/s11255-023-03532-1. PubMed
  • 182 Tubular Injury Causing Protracted GlycosuriaFollowing Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in theDevelopment of Protracted Hypoglycemia and Ketoacidosis. Tohoku J ExpMed.2021
    doi: 10.1620/tjem.255.291. PubMed
  • 179 Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition onBiomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized ControlledTrial. J Diabetes Res.2021
    doi: 10.1155/2021/7382620. PubMed
  • 138 Effect of linagliptin on oxidative stress markers in patientswith type 2 diabetes: a pilot study. Diabetol Int.2018 PubMed
  • 136 Effect of canagliflozin, a sodium glucose co-transporter 2inhibitor, on cisplatin-induced nephrotoxicity in mice. NaunynSchmiedebergs Arch Pharmacol.2018 PubMed
  • 129 Anagliptin ameliorates albuminuria and urinary liver-type fattyacid-binding protein excretion in patients with type 2 diabetes with nephropathy in aglucoselowering-independent manner. BMJ Open Diabetes Res Care.2017 PubMed
  • 126 Role of bardoxolone methyl, a nuclear factor erythroid 2-relatedfactor 2 activator, in aldosterone- and salt-induced renal injury. Hypertens Res.2017 PubMed
  • 125 Renoprotective effect of the xanthine oxidoreductase inhibitorTopiroxostat under decreased angiotensin II type 1a receptor expression. Eur J Pharmacol. 2017 PubMed
  • 115 The protective effect of human atrial natriuretic peptide onrenal damage during cardiac surgery. J Anesth.2016 PubMed
  • 113 The association between urinary liver-type fatty acid-bindingprotein and chronic kidney disease classification in HIV-infected Japanese patients. Clin Exp Nephrol.2016 PubMed
  • 107 Impact of teneligliptin on oxidative stress and endothelialfunction in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol.15(1): 76, 2016. PubMed
  • 106 Renoprotective effect of the xanthine oxidoreductase inhibitor,Topiroxostat,on Adenine-Induced Renal Injury. Am J Physiol RenalPhysiol.310(11):F1366-1376, 2016. PubMed
  • 96 Epoetin beta pegol alleviates oxidative stress and exacerbationof renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritisrats. Physiol Rep.3(12), 2015. PubMed
  • 91 Urinary ACE2 is associated with urinary L-FABP and albuminuria inpatients with chronic kidney disease. Scand J Clin LabInvest.75(5): 421-427, 2015. PubMed
  • 89 Does elevation of serum creatinine in patients with chronichepatitis C under therapy of telaprevir mean renal impairment? Nephrology.10(4):e0122212, 2015. PubMed
  • 85 Renoprotective effects of febuxostat in hyperuricemic patientswith chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol.19(6): 1044-1053, 2015. PubMed
  • 62 A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reducesrenal tubulointerstitial fibrosis by suppressing PAI-1. Am J Physiol RenalPhysiol.305(12): F1796-1803, 2013. PubMed
  • 58 Spironolactone diminishes urinary albumin excretion in patientswith type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med.29(8): e184-190, 2012. PubMed
  • 56 Renoprotective and antioxidant effects of cilnidipine inhypertensive patients. Hypertens Res.35(11): 1058-1062, 2012. PubMed
  • 51 Potential Benefit of Statin Therapy for Dyslipidemia with ChronicKidney Disease: Fluvastatin Renal Evaluation Trial (FRET). InternalMedicine.50(12): 1273-1278, 2011. PubMed
  • 50 Additive antioxidative effects of azelnidipine on angiotensinreceptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res .34: 935-941, 2011. PubMed
  • 39 Comparative effects of benidipine and amlodipine on proteinuria,urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidneydisease. Am J Med Sci.339(2): 157-163, 2010. PubMed
  • 38 Renoprotective Effects of Various Angiotensin II ReceptorBlockers in Patients with Early-Stage Diabetic Nephropathy. Kidney BloodPress Res.33(3): 213-220, 2010. PubMed
  • 37 Effects of telmisartan and enalapril on renoprotection inpatients with mild to moderate chronic kidney disease. Eur J ClinInvest.40(9): 790-796, 2010. PubMed
  • 35 Urinary L-type fatty acid-binding protein can reflect renaltubulointerstitial injury. Am J Pathol.174(4): 1203-1211, 2009. PubMed
  • 33 Tubular and glomerular injury in diabetes and the impact of ACEinhibition. Diabetes Care.32(9): 1684-1688, 2009. PubMed
  • 26 Renal L-type fatty acid-binding protein mediates the bezafibratereduction of cisplatin-induced acute kidney injury. KidneyInt.73(12): 1374-1384, 2008. PubMed
  • 25 Renoprotective effect of telmisartan in patients with chronickidney disease. Clin Exp Hypertens.30(7): 662-672, 2008. PubMed
  • 24 Additional renoprotective effects of azelnidipine combined withangiotensin receptor blockers in patients with diabetic nephropathy. ClinNephrol.70(5): 385-392, 2008. PubMed
  • 21 Angiotensin II receptor antagonist reduces urinary liver-typefatty acid-binding protein levels in patients with diabetic nephropathy and chronic renalfailure. Diabetologia.50(2): 490-492, 2007. PubMed
  • 20 Azelnidipine reduces urinary protein excretion and urinaryliver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci.333(6): 321-326, 2007. PubMed
  • 19 Beneficial effects of olmesartan and temocapril on urinaryliver-type fatty acid-binding protein levels in normotensive patients with immunoglobin Anephropathy. Am J Hypertens.20(11): 1195-1201, 2007. PubMed
  • 15 Urinary liver-type fatty acid-binding protein levels fordifferential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effectof low-density lipoprotein apheresis. Clin Nephrol.65(1): 1-6,2006. PubMed
  • 14 Effect of pioglitazone on urinary liver-type fatty acid-bindingprotein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev.22(5): 385-389, 2006. PubMed
  • 13 Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-BindingProtein in Patients with Chronic Renal Failure and Anemia. Am JNephrol.26(3): 276-280, 2006. PubMed
  • 12 Effect of pitavastatin on urinary liver-type fatty-acid-bindingprotein in patients with nondiabetic mild chronic kidney disease. Am JNephrol.26(1): 82-86, 2006. PubMed
  • 7 Candesartan reduces urinary fatty acid-binding protein excretionin patients with autosomal dominant polycystic kidney disease. TAm J MedSci.330(4): 161-165, 2005. PubMed
  • 6 Effect of Pitavastatin on Urinary Liver-Type Fatty Acid?BindingProtein Levels in Patients With Early Diabetic Nephropathy. DiabetesCare.28(11): 2728-2732, 2005. PubMed


Download product leaflet

For nonclinical safety evaluation

Urinary L-FABP kits for Rat, Dog, Cat, Monkey and Pig are available for the purpose of monitoring drug nephrotoxicity and drug effectiveness.
Top ▲ Home ▶